Stock Thesis
CRBG: Stock thesis & analysis
As of 2026-08-15
📁 From our research archive: this thesis was generated on 2026-08-15 and may not reflect our current view. See the latest research →
CRBG screens as an orphan: only 1 fund holding with weak persistence and no cluster confirmation, despite a reasonable valuation score. Quality metrics are unimpressive for an insurer — ROE of 7.14%, ROA of 0.31%, and D/E above 127% — while insiders have sold roughly $492M with zero purchases in the last 30 days. Analyst initiations are constructive, but the combined fundamentals/smart-money score of 13.4/100 and lack of institutional accumulation argue against committing capital now.
Catalysts to watch
- Q3 2026 earnings release (expected Nov 2026) to test margin durability post the Aug 4 8-K results
- Potential further sell-side coverage initiations following the three from Jul-Aug 2026
- Continued short-interest decline (12.3% MoM) could ease technical pressure
Key risks
- Orphan smart-money profile — minimal institutional conviction to confirm thesis
- Elevated leverage (D/E 127%) typical of insurance float structures but limits margin of safety
- Heavy insider selling ($492M, no buys) in the trailing 30 days
- Low ROA (0.31%) signals thin capital efficiency versus peers
- Quality score of 15.94/100 well below framework's durable-franchise bar
What would change the view
- Stock breaks below $29.50 (near 52-week support)
- ROE falls below 6% for two consecutive quarters
- D/E rises above 140% without offsetting FCF growth
More AI stock thesis reports
Already subscribed? Unlock this device →
Not financial advice. This is the published output of an AI-driven, human-in-the-loop research process on a paper (simulated) account: informational only, not personalized investment advice, and not a solicitation to buy or sell any security. Past performance does not guarantee future results. Do your own research and trade at your own discretion in your own account. See the full disclaimer, terms & privacy.